Practical Dermatology

09/27/2025

👩‍⚕️ 🩺 🤝 YMDC MENTORSHIP SESSION: Dr. Tina Bhutani

In this "Ask Me Anything" YoungMD Connect Mentorship session, Tina Bhutani, MD, MAS, FAAD, talks about her career path, which led her from academia to private practice. Dr. Bhutani also takes questions from the session attendees, which yield even more nuances and insights.✨

📺 Watch here ➡️ https://ow.ly/GjkV50X3eB5

Tina Bhutani, MD, MAS, FAAD, describes her career journey and answers various questions from YoungMD Connect members.
YoungMD Connect is an...

09/25/2025

🎙️👨‍⚕️👩‍⚕️👨‍⚕️ NEW PRACTICAL DERM PODCAST: Jason E. Hawkes, MD, MS, FAAD, discusses a recent consensus paper defining on-treatment remission for plaque psoriasis, and Theodore Rosen, MD, FAAD, joins associate medical editor Elizabeth (Lisa) Swanson, MD, FAAD, to discuss the threat posed by antimicrobial resistance and play “Two Truths and a Lie.” ✔️✔️❌

🎧 Listen here ➡️ https://ow.ly/w19n50X1EsW

Jason E. Hawkes, MD, MS, FAAD, discusses a recent consensus paper defining on-treatment remission for plaque psoriasis, and Theodore Rosen, MD,...

09/24/2025

🧴 🩺NEW: Allopurinol-induced SCARs like SJS and DRESS remain rare—but a new model can help dermatologists predict who’s at higher risk, providing evidence-based thresholds to guide therapy.✨

Read more ➡️ https://ow.ly/lRBq50X1C64

09/23/2025

🧬📊 DUPILUMAB IN SKIN OF COLOR: In a new retrospective chart review of adults with atopic dermatitis, Black patients reported fewer adverse events than White patients, even though findings were not statistically significant.

Read more ➡️ https://ow.ly/T5tz50X1cSC

09/22/2025

🔎 📉 NICOTINAMIDE AND SKIN CANCER RISK: A new study of data from 33,000+ VA patients show that nicotinamide supplementation (500 mg BID) is linked to reduced skin cancer risk, with a 54% reduction when started after the first skin cancer. The strongest effect was seen for cutaneous squamous cell carcinoma.🏥

Read more ➡️ https://ow.ly/Qgcn50X0xkt

09/19/2025

📢 BIMEKIZUMAB UPDATE: At in Paris, UCB presented new long-term data showing sustained effect in two differen diseases:
✔️3-year durability in hidradenitis suppurativa, including sustained HiSCR100 and IHS4-100 response rates
✔️4-year plaque psoriasis data showing nearly half of patients maintained PASI 0 throughout

📖 Read our coverage ➡️ https://ow.ly/QPiz50WZwX5

09/18/2025

🎙️👨‍💼C-SUITE CHAT: In this edition, John Aylworth, PhD, CEO and founder of XYTOGEN BIOTECH INC Biotech, talks about the growing demand for regenerative treatments in dermatology and new options for the treatment room.✔️

Read more ➡️ https://ow.ly/N0yP50WYN9S

John Aylworth, PhD, CEO and founder of Xytogen Biotech, talks about the growing demand for regenerative treatments in dermatology and new options...

09/17/2025

📢 🥇 NEW: Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced that ZORYVE® (roflumilast), its once-daily, steroid-free topical for treating atopic dermatitis, psoriasis, and seborrheic dermatitis, has been recognized by Allure Magazine with a 2025 Best of Beauty Breakthrough Award—the first prescription product across these indications to receive the honor. 🧴👨‍🔬

Read more ➡️ https://ow.ly/AXCA50WYpPE

09/16/2025

📊 🔎 IMMUNOSUPPRESSANTS AND TB RISK: A large analysis of more than 135 million patient records revealed elevated TB risk in patients treated with systemic immunosuppressants (IL-17, IL-23, IL-12/23, JAK inhibitors, cyclosporine, and TNF-α inhibitors). Only IL-4/13 inhibitors (e.g., dupilumab) did not show increased risk.

Read more ➡️ https://ow.ly/1Eqe50WXFqH

09/15/2025

✍️ ✨ON GETTING WHAT YOU WANT: In the September 2025 editorial for Practical Dermatology, Neal Bhatia, MD, reflects on mentorship, professional legacy, and the importance of paying it forward in medicine, urging dermatologists to support one another amid evolving practice models, burnout, and shifting expectations.🏥✔️

Read Dr. Bhatia's column ➡️ https://ow.ly/tpH350WXbvt

Professionally and personally, it’s hard to avoid the “what if” and “if only” scenarios. But when those thoughts outweigh the pride in where we’ve...

09/12/2025

📢 📰 SEPTEMBER ISSUE IS LIVE: For our Cover Focus this month, Practical Dermatology dives deep into the evolving relationship between dermatology practices and private equity. The issue is explored from a number of different perspectives from the field, including that of practicing dermatologists, practice owners, financial advisors, acquisition consultants, and more. 🔎 👨‍🔬👩‍⚕️

💡 Key topics:
• Benefits and drawbacks of PE involvement
• The M&A market outlook in aesthetics
• The ESOP model as a compelling alternative
• Expert insights on navigating PE-era recruitment

📖 Read the full issue here → https://ow.ly/fJzS50WVYkh

09/11/2025

🎙️👨‍🔬C-SUITE CHAT: On the latest episode, Zai Lab is working on an IL-13/IL-31R bispecific antibody for the treatment of atopic dermatitis, and who better to talk about the work than the head of global research and development, Rafael Amado, MD? In this interview, Dr. Amado discusses recently presented data given at the European Academy of Allergy and Clinical Immunology Congress 2025.

Watch here.➡️

Rafael Amado, MD, head of global research and development for Zai Lab, discusses new preclinical data presented at the European Academy of Allergy...